Abstract
The Early Manifest Glaucoma Trial (EMGT) was a randomized, placebo-controlled clinical trial in patients with newly detected, previously untreated, primary open-angle glaucoma (POAG) to determine whether immediate institution of intraocular pressure (IOP)–lowering therapy reduces the risk of progression compared to delayed treatment or observation. The study showed that IOP-lowering therapy offered a definitive benefit in patients with early glaucoma by delaying progression of glaucomatous optic neuropathy, especially in eyes with higher IOPs (>21 mm Hg) at baseline. Even modest reduction in IOP decreased the risk of progression. However, a large percentage of treated eyes still showed progression during follow-up. The progression of glaucomatous optic neuropathy was highly variable and difficult to predict for an individual patient.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
